Abstract HIV-1 vaccine design aims to develop an immunogen that elicits broadly neutralizing antibodies against a desired epitope, while eliminating responses to off-target regions of HIV-1 Env. We report characterization of Ab1245, an off-target antibody against the Env gp120-gp41 interface, from V3-glycan patch immunogen-primed and boosted macaques. A 3.7 Å cryo-EM structure of an Ab1245-Env complex reveals one Ab1245 Fab binding asymmetrically to Env trimer at the gp120-gp41 interface using its long CDRH3 to mimic regions of gp41. The mimicry includes positioning of a CDRH3 methionine into the gp41 tryptophan clasp, resulting in displacement of the fusion peptide and fusion peptide-proximal region. Despite fusion peptide displacement, Ab...
SIVmac239 infection of macaques is a favored model of human HIV infection. However, the SIVmac239 en...
The HIV fusion peptide (FP) is a promising vaccine target. FP-directed monoclonal antibodies from va...
The development of an effective HIV-1 vaccine remains a scientific and global health priority despit...
The induction of broadly HIV-1 neutralizing antibodies (bNAbs) by vaccination is challenging, but un...
The induction by vaccination of broadly neutralizing antibodies (bNAbs) capable of neutralizing vari...
Although vaccines are important in preventing viral infections by inducing neutralizing antibodies (...
A component to the problem of inducing broad neutralizing HIV-1 gp41 membrane proximal external regi...
<div><p>Eliciting broadly neutralizing antibodies (bnAbs) targeting envelope (Env) is a major goal o...
Eliciting broadly neutralizing antibodies (bnAbs) targeting envelope (Env) is a major goal of HIV va...
The HIV-1 envelope (Env) glycoprotein is the sole HIV-1 surface protein recognized by the humoral an...
The fusion peptide (FP) of HIV-1 envelope glycoprotein (Env) is essential for mediating viral entry....
The induction of broad and potent immunity by vaccines is the key focus of research efforts aimed at...
A small fraction of HIV-1- infected humans develop broadly neutralizing antibodies (bNAbs) against H...
Despite the isolation of several broadly neutralizing anti-HIV antibodies from infected patients, no...
The induction of broad and potent immunity by vaccines is the key focus of research efforts aimed at...
SIVmac239 infection of macaques is a favored model of human HIV infection. However, the SIVmac239 en...
The HIV fusion peptide (FP) is a promising vaccine target. FP-directed monoclonal antibodies from va...
The development of an effective HIV-1 vaccine remains a scientific and global health priority despit...
The induction of broadly HIV-1 neutralizing antibodies (bNAbs) by vaccination is challenging, but un...
The induction by vaccination of broadly neutralizing antibodies (bNAbs) capable of neutralizing vari...
Although vaccines are important in preventing viral infections by inducing neutralizing antibodies (...
A component to the problem of inducing broad neutralizing HIV-1 gp41 membrane proximal external regi...
<div><p>Eliciting broadly neutralizing antibodies (bnAbs) targeting envelope (Env) is a major goal o...
Eliciting broadly neutralizing antibodies (bnAbs) targeting envelope (Env) is a major goal of HIV va...
The HIV-1 envelope (Env) glycoprotein is the sole HIV-1 surface protein recognized by the humoral an...
The fusion peptide (FP) of HIV-1 envelope glycoprotein (Env) is essential for mediating viral entry....
The induction of broad and potent immunity by vaccines is the key focus of research efforts aimed at...
A small fraction of HIV-1- infected humans develop broadly neutralizing antibodies (bNAbs) against H...
Despite the isolation of several broadly neutralizing anti-HIV antibodies from infected patients, no...
The induction of broad and potent immunity by vaccines is the key focus of research efforts aimed at...
SIVmac239 infection of macaques is a favored model of human HIV infection. However, the SIVmac239 en...
The HIV fusion peptide (FP) is a promising vaccine target. FP-directed monoclonal antibodies from va...
The development of an effective HIV-1 vaccine remains a scientific and global health priority despit...